免疫检查点抑制剂相关胰腺炎的影像学表现
回顾性纳入25例接受免疫检查点抑制剂治疗且临床和/或生化证据提示胰腺炎的患者,分析对比增强CT、MRI和18F-FDG PET/CT表现。影像多表现为弥漫或局灶性胰腺增大、不均匀强化及胰周浸润,80%符合急性间质性胰腺炎,未见坏死性胰腺炎或假性囊肿,44%出现胰腺萎缩。
要点
- 免疫检查点抑制剂相关胰腺炎多表现为局灶或弥漫性急性间质性胰腺炎,CT严重指数均<3提示轻度。
- 急性期影像表现经治疗后全部消退,但44%(11/25)出现胰腺萎缩。
- 未见坏死性胰腺炎或假性囊肿等局部急性并发症。
关键影像表现/征象
- 胰腺弥漫性增大14例,局灶性增大11例。
- 胰腺不均匀强化21例。
- 对比增强CT和MRI显示胰周浸润呈局灶性9例、弥漫性15例。
- 符合急性间质性胰腺炎模式20/25(80%),符合自身免疫性胰腺炎模式4/25(16%),混合模式1例(4%)。
- 18F-FDG PET/CT显示胰腺局灶性FDG摄取增高2/3(66%)。
诊断标准与关键数值
- 急性间质性胰腺炎模式20/25(80%)。
- 自身免疫性胰腺炎模式4/25(16%)。
- 混合模式1/25(4%)。
- 所有患者CT严重指数<3,符合轻度胰腺炎。
- 18F-FDG PET/CT胰腺局灶性FDG摄取增高2/3(66%)。
临床应用与阅片要点
- 影像上免疫检查点抑制剂相关胰腺炎多表现为局灶或弥漫性急性间质性胰腺炎,可伴胰周浸润和胰腺不均匀强化。
- 所有患者CT严重指数<3提示轻度,未见坏死性胰腺炎或假性囊肿。
- 胰腺炎后萎缩在随访中常见(11/25,44%)。
- 18F-FDG PET/CT可显示胰腺局灶性FDG摄取增高,但仅2/3患者可见。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To describe contrast-enhanced computed tomography (CECT), 18-Fluorine (18F)-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT and magnetic resonance imaging (MRI) findings of immune checkpoint inhibitor (ICI) associated pancreatitis in patients undergoing immunotherapy for solid malignant tumours.
METHOD: In this retrospective study, 25 patients with clinical and/or biochemical evidence of pancreatitis who underwent CECT, MRI and 18F-FDG-PET/CT while being treated with ICIs were included. Imaging features of acute pancreatitis included: pancreatic enlargement, heterogeneous enhancement, peripancreatic stranding, fluid collection, pseudocyst, necrosis, atrophy and calcification. 18F-FDG PET/CT imaging was reviewed for pattern of abnormally increased pancreatic FDG uptake. ICI-associated pancreatitis diagnosis was based on clinical, imaging and biochemical findings.
RESULTS: Imaging findings of ICI-associated pancreatitis included diffuse (n = 14) or focal (n = 11) pancreatic enlargement; heterogenous enhancement (n = 21); focal (n = 9) or diffuse (n = 15) peripancreatic infiltration on CECT and MRI. A pattern consistent with acute interstitial pancreatitis was present in 20/25 (80 %) patients, and a pattern consistent with autoimmune pancreatitis in 4/25 (16 %). A mixed pattern was present in one patient (4%). No patient developed necrotizing pancreatitis or a pseudocyst. The CT severity index was < 3 in all patients, consistent with mild pancreatitis. Focal pancreatic FDG uptake was noted in 2/3 (66 %) of patients. Acute imaging findings resolved with treatment in all 25 patients. Pancreatic atrophy developed in 11/25 (44 %).
CONCLUSIONS: ICI-associated pancreatitis typically presents as either focal or diffuse acute interstitial pancreatitis. Post-pancreatitis atrophy is common. The ICI-associated pancreatitis cases in our study were mild, managed conservatively and did not result in local acute complications.
引用
- Das JP, Postow MA, Friedman CF, et al. Imaging findings of immune checkpoint inhibitor associated pancreatitis. Eur J Radiol. 2020. PMID: 32905952. doi:10.1016/j.ejrad.2020.109250
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。